RNA
Atrium Therapeutics, Inc. (NASDAQ)
Healthcare — Biotechnology
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
Price History
Fundamentals
| Market Cap | $227.51M |
| P/E Ratio (TTM) | - |
| Forward P/E | -2.27 |
| EPS (TTM) | $-5.02 |
| Dividend Yield | - |
| Profit Margin | -159.99% |
| Revenue Growth | 1148.30% |
| ROE | - |
| Debt/Equity | 1.15 |
| Recommendation | Strong Buy 1.0 |
| Analyst Target | $25.00 |
| Analysts | 3 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 74.3 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $16.77 |
| 52-Week Low | $11.40 |
| 50-Day Avg | $12.88 |
| 200-Day Avg | $13.33 |
| Avg Volume | 299.3K |
| Volume | 143.5K |
Performance Analysis
NEUTRALRNA presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:29 UTC
Back to Screener Export Report